-
Posted by
Two Blokes Jul 7 -
Filed in
Stock
-
7 views
Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds, but is pivoting to larger in-vivo gene editing liver disease targeting opportunities. PRME is prioritizing in-vivo gene editing therapy programs targeting Wilson's Disease and Alpha-1 Antitrypsin Deficiency, with IND filings expected in H1 and mid-2026, respectively. These new programs use in-vivo LNP delivery, target larger markets, and could provide substantially better advantages for PRME over ex-vivo gene editing.
